Journal of Clinical & Experimental Pharmacology

Abstract

BTF3-Promoter Based Screening of Anti- Human Breast Cancer Compounds

Kavita Rawat, Wahajul Haq and Raj Kamal Tripathi

Basic Transcription Factor 3 (BTF3) is a Transcription factor known to differentially express in different forms of cancer; where in gastric cancer, silencing of BTF3 induced apoptosis. Previously, we reported Human β casein fragment 54-59 (NS) down modulates BTF3 expression in Human THP-1 cells. In the present study, we developed an in vitro model targeting BTF3 Promoter for screening of compounds down regulating BTF3 and to study the impact of BTF3 down regulation on apoptosis in MCF-7 cell line. We further confirmed the efficacy of NS to down regulate BTF3 in MCF-7 cells through western blotting. NS and its analogs AN1, AN2 and AN3 were screened on BTF3 promoterreporter construct during transient transfection in MCF-7 cell line, where the expression of reporter was found to be down regulated upon treatment. This study was further confirmed by immunoblotting which produced similar results in MCF-7 cells. To determine the biological function on suppressing BTF3 expression by NS and analogs, cell viability assay and Annexin-V-FITC staining were performed, the results clearly demonstrated an increase in apoptosis on BTF3 down regulation in MCF-7 cells. In conclusion, BTF3 expression is a crucial biomarker in breast cancer therapy and our model can be an asset for fast screening of compounds modulating BTF3 expression in different cancer forms, where it is found to be overexpressed.